ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Misses Revenue Estimates

Stock Information for ImmunoPrecise Antibodies Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ImmunoPrecise Antibodies Ltd.

IPA's LENSai(TM) Platform Delivers X-Ray-Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai(TM) with FDA's Shift to Non-Animal Testing Methods
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025
ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.
IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025
IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy
ImmunoPrecise Antibodies Announces Key Leadership Changes

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.